Clinical Trial Update: A Trial of Niraparib in Platinum-Sensitive Castration-Resistant Prostate Cancer With DNA Repair Defects [Phase 2]

View source ↗

Summary

Phase 2 trial of niraparib in platinum-sensitive castration-resistant prostate cancer with DNA repair defects completed; results posted on 2026-03-04.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Niraparib (Niraparib)

Snippet

Sponsor: Abramson Cancer Center at Penn Medicine | Conditions: Prostate Adenocarcinoma | Phase 2 | Status: COMPLETED | Results posted: 2026-03-04